INDP Stock Overview
A clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Indaptus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.00 |
| 52 Week High | US$3.10 |
| 52 Week Low | US$0.84 |
| Beta | 1.13 |
| 11 Month Change | -25.93% |
| 3 Month Change | -38.27% |
| 1 Year Change | -52.38% |
| 33 Year Change | -82.73% |
| 5 Year Change | n/a |
| Change since IPO | -88.73% |
Recent News & Updates
Recent updates
Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?
Mar 27
Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?
Aug 15Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45
Aug 08Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications
Sep 29Shareholder Returns
| INDP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.9% | 2.5% | 2.2% |
| 1Y | -52.4% | 16.1% | 31.6% |
Return vs Industry: INDP underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: INDP underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| INDP volatility | |
|---|---|
| INDP Average Weekly Movement | 16.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INDP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INDP's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Jeff Meckler | indaptusrx.com |
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.
Indaptus Therapeutics, Inc. Fundamentals Summary
| INDP fundamental statistics | |
|---|---|
| Market cap | US$10.20m |
| Earnings (TTM) | -US$14.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs INDP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.89m |
| Earnings | -US$14.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.46 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did INDP perform over the long term?
See historical performance and comparison